Oral Anticoagulant Treatment in Patients with Atrial Fibrillation and Chronic Kidney Disease

Over the past few decades, a series of innovative medicines have been developed in order to optimize anticoagulation therapy for atrial fibrillation (AF). As a result, a number of nonvitamin K antagonist oral anticoagulants (NOAC) that directly target the enzymatic activity of factor II and factor X...

Descripción completa

Detalles Bibliográficos
Autores principales: Stoica, Mihai Ciprian, Gáll, Zsolt, Gliga, Mirela Liana, Căldăraru, Carmen Denise, Székely, Orsolya
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8147111/
https://www.ncbi.nlm.nih.gov/pubmed/33925501
http://dx.doi.org/10.3390/medicina57050422

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8147111/
https://www.ncbi.nlm.nih.gov/pubmed/33925501
http://dx.doi.org/10.3390/medicina57050422

Ejemplares similares